Meningococcal Infections
📧 Sign up to get email alerts when something new happens for Meningococcal Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults [Phase 3]
Phase 3 trial update assessing the effectiveness of GlaxoSmithKline's meningococcal Group B and ABCWY vaccines in healthy adolescents and yo…
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea [Phase 4]
Postmarketing surveillance study (Phase 4) evaluating Menactra in the Republic of Korea has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) [Phase 4]
Phase 4 trial update evaluating the immunogenicity of the U.S.-licensed meningococcal serogroup B vaccine Trumenba; study completed with res…
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers [Phase 3]
Phase 3 trial update on the immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in toddlers has com…
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years [Phase 3]
Phase 3 study of an investigational quadrivalent meningococcal conjugate vaccine in children aged 2 to 9 years has completed with results po…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents [Phase 2]
Phase 2 trial evaluating the immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in healthy adolesc…
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children [Phase 3]
Phase 3 trial update evaluating immunogenicity and safety of a booster dose of a quadrivalent meningococcal conjugate vaccine in children.
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine [Phase 3]
Phase 3 trial update on immunogenicity and safety of a booster dose for an investigational quadrivalent meningococcal conjugate vaccine; stu…
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers [Phase 2]
Phase 2 trial updating immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in healthy toddlers; res…
-
CLINICAL_TRIALS trial_result · 2020-03-09Clinical Trial Update: Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine [Phase 3]
Phase 3 trial update evaluating immune lot consistency, immunogenicity, and safety of an investigational quadrivalent meningococcal conjugat…
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older [Phase 3]
Phase 3 trial assessing immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in adults 56 and older;…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination [Phase 3]
A Phase 3 trial comparing long-term antibody persistence of MenACWY-TT (GSK134612) with Mencevax ACWY in healthy adolescents and adults, plu…
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612 [Phase 3]
Phase 3 trial assessing persistence of antibodies after vaccination with meningococcal vaccine GSK134612 has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-06-17Clinical Trial Update: Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children [Phase 3]
Phase 3 trial update evaluating persistence of antibodies after meningococcal vaccine PF-06866681 in healthy children; results posted in 201…
-
CLINICAL_TRIALS trial_result · 2019-04-01Clinical Trial Update: Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations [Phase 4]
Phase 4 trial evaluating antibody persistence after four MenACWY vaccinations; completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines [Phase 3]
Phase 3 trial evaluating the immunogenicity and safety of Meningococcal vaccine GSK 134612 when co-administered with pneumococcal and DTPa-H…
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children [Phase 3]
Phase 3 persistence and booster study of GSK134612 meningococcal vaccine in healthy children completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination [Phase 3]
Phase 3 trial updating immunogenicity, reactogenicity, and safety of GlaxoSmithKline's MenACWY-TT meningococcal vaccine when administered si…
-
CLINICAL_TRIALS trial_result · 2018-12-28Clinical Trial Update: Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects [Phase 2]
Phase 2 clinical trial comparing GSK134612 in individuals previously vaccinated against meningococcal disease to non-vaccinated individuals;…
-
CLINICAL_TRIALS trial_result · 2018-11-26Clinical Trial Update: Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds [Phase 3]
Phase 3 trial comparing immunogenicity and safety of GSK 134612 meningococcal vaccine to Mencevax ACWY in healthy adults 18-25; results post…
-
CLINICAL_TRIALS trial_result · 2018-09-14Clinical Trial Update: Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers. [Phase 2]
Phase 2 trial update on immunogenicity and safety of the meningococcal vaccine GSK134612 given in 1 or 2 doses to healthy 9–12 month old tod…
-
CLINICAL_TRIALS trial_result · 2018-08-23Clinical Trial Update: The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers [Phase 2]
Phase 2 trial update on long-term antibody persistence of GSK134612 meningococcal vaccine in healthy toddlers; results posted after completi…
-
CLINICAL_TRIALS trial_result · 2018-08-22Clinical Trial Update: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants [Phase 3]
Phase 3 trial assessing safety and immunogenicity of GlaxoSmithKline meningococcal group B vaccine given with MenACWY conjugate vaccine in h…
-
CLINICAL_TRIALS trial_result · 2018-08-03Clinical Trial Update: Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination [Phase 3]
A Phase 3 clinical trial evaluated safety and immunogenicity of a single-dose MenACWY-CRM vaccine (Menveo) in individuals aged 15-55, about …
-
CLINICAL_TRIALS trial_result · 2018-07-03Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults [Phase 3]
Phase 3 immunogenicity and safety study evaluating GlaxoSmithKline's meningococcal vaccine with or without co-administration of Cervarix and…